Updated:
Deerpath Capital Management
Deerpath Capital Management was founded in 2005, positioned from the start as a dedicated direct lender to the lower middle market.
Deerpath Capital Management
Deerpath Capital Management was founded in 2005, positioned from the start as a dedicated direct lender to the lower middle market. Founding partners James Ely and David Markman evolved the firm from an initial focus on corporate debt into a broader private credit platform. The firm targets control and non-control investments in senior secured loans, unitranche facilities, and junior capital, typically backing sponsor-led buyouts in healthcare, business services, and industrial end markets. Portfolio companies have included Avantor's pre-IPO debt (2019), along with direct loans to firms such as Premise Health and Savage Services (per SEC filings and public statements). Geographically, the firm originates across the United States, with concentrated activity in the Southeast, Midwest, and Mid-Atlantic regions. As of late 2023, Deerpath had raised a series of institutional funds, the most recent being Deerpath Private Capital Fund VI, which closed in 2021 per SEC Form D filings. The firm employs roughly 30 professionals across its New York headquarters and Atlanta office, and has formal ties to the healthcare-focused lender Deerpath Healthcare Credit Partners. In 2024, Deerpath was involved in financing the recapitalization of a portfolio company in its direct loan portfolio, though specific deal details were not publicly flagged by the firm. The structural differentiator is Deerpath's strict lower-middle-market orientation: most originations fall in the $10M–$75M hold size, where the firm acts as lead arranger — a position that many larger direct lenders cannot economically occupy. This gives Deerpath proprietary flow that bypasses the broadly syndicated market.
General information
Firm type
Private Credit Manager
Year founded
2005
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Additional offices
Atlanta, GA, United States
Principals
James S. Ely III
Managing Partner and Chief Executive Officer
David D. Markman
Managing Partner and Chief Investment Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Deerpath Capital?
Investment decisions are led by Managing Partners James S. Ely III (CEO) and David D. Markman (CIO), each with over 25 years of private credit experience (per the firm's official communications). The team includes sector-focused investment professionals who source and underwrite loans directly.
How does Deerpath source proprietary deal flow?
Deerpath originates directly from its focus on the lower middle market — companies with $5M–$50M EBITDA. In this segment, large competitors like Ares or Apollo often do not lead transactions, allowing Deerpath to build direct relationships with private equity sponsors and business owners (per public records and SEC filings).
Does Deerpath participate in fund commitments or only direct deals?
Deerpath operates primarily as a direct lender, making senior secured loans and unitranche facilities. It also manages commingled funds — most recently Deerpath Private Capital Fund VI — through which institutional investors gain exposure to its direct lending portfolio (per SEC Form D).
What investment stages does Deerpath typically target?
Deerpath targets sponsor-led buyouts and recapitalizations in the lower middle market, with hold sizes typically between $10M and $75M. The firm focuses on senior secured and unitranche debt, avoiding junior capital or equity investments.
Which sectors does Deerpath explicitly avoid?
Deerpath avoids lending to cyclical or highly regulated industries such as energy exploration, real estate development, and banking (per the firm's stated investment parameters and public commentary from principals).
How is Deerpath related to Deerpath Healthcare Credit Partners?
Deerpath Healthcare Credit Partners appears as a separate investment vehicle or vehicle series within the Deerpath platform, focused exclusively on healthcare-services loans (per SEC filings and marketing materials). The two share common principals but operate as distinct funds.
Where does Deerpath's underlying capital come from?
Deerpath manages institutional capital from pension funds, endowments, insurance companies, and family offices (per the firm's standard marketing language). The firm does not disclose the underlying family or endowment source of any co-mingled fund's base capital.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: